Kovo+ Holdings Inc. Secures Lead Order and Strategic Financing Commitments
Calgary, Alberta--(Newsfile Corp. - August 15, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") has secured lead order and strategic financing commitments. Kovo announces that, further to its news releases dated May 22, 2024, July 24, 2024, September 17, 2024, and December 19, 2024, Avonlea Ventures #2 Inc. ("AVI"), Kovo's largest shareholder and secured creditor, has (i) elected to convert up to $7,230,789 (USD $5,239,702) (the "Indebtedness
Technology, Healthcare and Hospitals, Internet Technology
2025-08-15 8:26 PM EDT | Kovo+ Holdings Inc.
VitalHub Announces Filing of Prospectus Supplement
Toronto, Ontario--(Newsfile Corp. - August 15, 2025) - VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is pleased to announce that, in connection with its previously announced "bought deal" public offering, it has filed a prospectus supplement dated August 15, 2025 (the "Prospectus Supplement") to the Company's base shelf prospectus dated July 23, 2025 (the "Base Shelf Prospectus") with the secur
Healthcare and Hospitals, Blockchain, Health
2025-08-15 8:05 PM EDT | VitalHub Corp.
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - August 14, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On August 14, 2025, the Issuer completed the fourth tranche (the "Fourth Tranche") of a private placement of units ("Units") an
Technology, Healthcare and Hospitals, Health
2025-08-14 5:14 PM EDT | James Anderson
MyndTec Inc. Completes Fourth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - August 14, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the fourth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The fourth tranche of the private placement consists of 688,610 Units of the Company (the "Units") at a price of $0
Technology, Healthcare and Hospitals, Health
2025-08-14 4:54 PM EDT | MyndTec Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of
Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-14 4:24 PM EDT | Elite Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-14 4:15 PM EDT | Phio Pharmaceuticals Corp.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), an innovative surface protection company using their technology to develop product solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, announces that it intends to consolidate the common shares of the Company (each, a "Share") on the basis of ten (10) pre-consolidation Shares
Technology, Healthcare and Hospitals, Health
2025-08-13 8:00 AM EDT | FendX Technologies Inc.
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone payments Following the transaction, Adaptimmune has repaid its debt and is restructuring to maximize
Biotechnology, Healthcare and Hospitals
2025-08-13 7:30 AM EDT | Adaptimmune Therapeutics PLC
HEALWELL Reports Record Revenue Growth of 645% in Q2-2025 and Achieves First Quarter of Positive Adjusted EBITDA
HEALWELL achieved quarterly revenue from continuing operations of $40.5 million in Q2-2025, 645% higher than the $5.4 million generated in Q2-2024. Revenue growth in the quarter was largely driven by the Orion Health acquisition, resulting in a record 1,064% year-over-year increase in the Company's Healthcare Software business compared to Q2-2024. During Q2-2025, HEALWELL reported positive Adjusted EBITDA of $1.9 million, compared to an Adjusted EB
Technology, Healthcare and Hospitals
2025-08-13 6:00 AM EDT | HEALWELL AI
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's potential Management to host conferenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-12 5:30 PM EDT | Medexus Pharmaceuticals Inc.
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING") to explore the clinical application of BioMark's innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader Nor
Technology, Biotechnology, Healthcare and Hospitals
2025-08-12 8:30 AM EDT | BioMark Diagnostics, Inc.
MyndTec Inc. Announces Planned Chief Financial Officer Transition
Mississauga, Ontario--(Newsfile Corp. - August 11, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, today announced a planned transition in its Chief Financial Officer role. Jing Peng has been appointed as the Company's new Chief Financial Officer, effective September 1, 2025. Scott Franklin, the Company's current CFO, will remain available to the Company through September 30, 2
Technology, Healthcare and Hospitals, Health
2025-08-11 5:30 PM EDT | MyndTec Inc.
Scryb Inc. Provides Early Warning Update on Holdings In Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - August 8, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb") is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer"). This press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids ("NI 62-104") and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues
Biotechnology, Healthcare and Hospitals, Health
2025-08-08 8:25 PM EDT | Scryb Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results
Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-08 4:30 PM EDT | Elite Pharmaceuticals, Inc.
Discovery Senior Living Selected to Operate 15 Ventas-Owned Communities, Expanding Discovery's Portfolio and Strategic Relationship
Bonita Springs, Florida--(Newsfile Corp. - August 8, 2025) - Discovery Senior Living ("Discovery" or the "Company") one of the nation's largest most trusted senior housing operators, is pleased to announce it has been selected by Ventas, Inc. ("Ventas") to assume operations of 15 senior living communities across multiple U.S. states. The transition marks an expansion of a multi-year, performance-driven relationship between the two companies and reinforces a shared commitment to operati
Healthcare and Hospitals, Real Estate, Housing
2025-08-08 9:02 AM EDT | Discovery Senior Living
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with Takeda (TSE: 4502) (NYSE: TAK), to produce Mesalazine MMX 1200 mg (marketed as Lialda® in the USA and as Mezavant in Europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for
Healthcare and Hospitals, Health
2025-08-08 1:18 AM EDT | Cosmo Pharmaceuticals N.V.
Scryb Announces Effective Date of Proposed Share Consolidation
Toronto, Ontario--(Newsfile Corp. - August 7, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) ("Scryb'' or the "Company"), is pleased to announce that further to its news release dated July 25, 2025, the Company will proceed with the consolidation of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) new Common Share for every ten (10) old Common Shares (the "Consolidation"), effective as of August 13, 2025. The Consolidation
Biotechnology, Healthcare and Hospitals, Health
2025-08-07 10:20 PM EDT | Scryb Inc.
PhantomOmics and Garden Loft Partner to Launch World's First Smart Modular Senior Homes with Embedded Health Scanning Technology
Calgary, Alberta--(Newsfile Corp. - August 7, 2025) - Two Alberta innovators, PhantomOmics Inc. and Garden Loft Construction Ltd., have announced a groundbreaking exclusive partnership to deploy biometric health scanning devices in modular senior housing across Canada. This bold move positions the partnership at the forefront of technology-enabled senior care and will enable individuals who can no longer manage living in their own home to maintain their independence and avoid a move int
Technology, Healthcare and Hospitals, Sensor, Health
2025-08-07 12:48 PM EDT | PhantomOmics Inc.
Adia Nutrition Inc. Celebrates Adia Med's Approval as a UnitedHealthcare Provider in $5.3 Trillion Healthcare Market
Winter Park, Florida--(Newsfile Corp. - August 6, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is proud to announce that its healthcare clinic, Adia Med, has been officially approved as a provider with UnitedHealthcare, effective as of August 1, 2025. This significant milestone positions Adia Med within the $5.3 trillion U.S. healthcare market [CMS National Health Expenditure Projections, 2024-2033], enabling the clinic to expand access to its innovative regenerative medicine treatments fo
Healthcare and Hospitals, Health
2025-08-06 11:43 AM EDT | Adia Nutrition Inc.
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum
Dublin, Ireland--(Newsfile Corp. - August 6, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies. Cosmo confirms that its operations and revenue streams are not impacted by any potential U.S. tariff measures, as the Company does not export products from Switzerland to the United States and operates on long-term contracts with global partners.
Healthcare and Hospitals, Health
2025-08-06 11:11 AM EDT | Cosmo Pharmaceuticals N.V.